Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells
✍ Scribed by Khanim, Farhat L; Gommersall, Lyndon M; Wood, Victoria HJ; Smith, Kirsty L; Montalvo, Leire; O'Neill, Laura P; Xu, Yue; Peehl, Donna M; Stewart, Paul M; Turner, Bryan M
- Book ID
- 110068841
- Publisher
- Nature Publishing Group
- Year
- 2004
- Tongue
- English
- Weight
- 294 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0950-9232
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The vitamin D receptor (VDR) is a member of the steroid/retinoid receptor superfamily of nuclear receptors and has potential tumor‐suppressive functions in prostate and other cancer types. Vitamin D~3~ (VD~3~) exerts its biological actions by binding within cells to VDR. The VDR then in
## Abstract We previously demonstrated that expression of androgen receptor (AR) by transfection of the androgen‐independent prostate cancer cell line PC3 decreases invasion and adhesion of these cells (PC3‐AR) through modulation of α6β4 integrin expression. The treatment with androgens further red
## Abstract Although many studies have examined the mechanisms of 1,25‐dihydroxyvitamin D~3~ (calcitriol or 1,25 D) action in different prostate cancer cell lines, little is known regarding the influence of this steroid on the normal prostate. The presence of both VDR and AR in normal prostatic tis
## Abstract Raloxifene (RAL), a selective estrogen receptor (ER) modulator (SERM) seems to induce apoptosis in both androgen‐dependent and ‐independent prostate cell (PC) lines via activation of ERβ and an antagonistic effect on ERα. In this study, we evaluated the effects of RAL on epithelial PC g